PD-0299685
Pharmaceutical compound
From Wikipedia, the free encyclopedia
PD-0299685 is a gabapentinoid (α2δ subunit-containing voltage-gated calcium channel blocker) which was under development for the treatment of insomnia and vasomotor symptoms (hot flashes) related to menopause as well as interstitial cystitis.[1][2][3] It is taken orally.[1] PD-0299685 was under development by Pfizer.[1] It reached phase 2 clinical trials prior to the discontinuation of its development.[1]
Other namesPD-0299685; PD-299685; PD0299685; PD299685; PD-299,685
ATC code
- None
| Clinical data | |
|---|---|
| Other names | PD-0299685; PD-299685; PD0299685; PD299685; PD-299,685 |
| Routes of administration | Oral[1] |
| Drug class | Gabapentinoid |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C10H21NO2 |
| Molar mass | 187.283 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
- List of investigational insomnia drugs
- Atagabalin (PD-0200390)